Mediwelcome Healthcare Management & Technology (HKSE:02159) EBIT: HK$9.3 Mil (TTM As of Dec. 2025)


HKSE:02159 Mediwelcome Healthcare Management & Technology Inc HKSE:02159
54 GF Score
Price HK$1.62
GF Value HK$0.69
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Mediwelcome Healthcare Management & Technology EBIT?

Mediwelcome Healthcare Management & Technology HKSE:02159 54 EBIT is HK$9.3 Mil as of Dec. 2025. GuruFocus rates HKSE:02159 with a GF Score™ of 54/100 and a GF Value™ of HK$0.69 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Mediwelcome Healthcare Management & Technology's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$13.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$9.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Mediwelcome Healthcare Management & Technology's annualized ROC % for the quarter that ended in Dec. 2025 was 21.13%. Mediwelcome Healthcare Management & Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 111.17%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Mediwelcome Healthcare Management & Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 2.45%.

Mediwelcome Healthcare Management & Technology  (HKSE:02159) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Mediwelcome Healthcare Management & Technology's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=27.66 * ( 1 - 0% )/( (151.276 + 110.579)/ 2 )
=27.66/130.9275
=21.13 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=239.536 - 40.902 - ( 103.01 - max(0, 161.041 - 208.399+103.01))
=151.276

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=210.436 - 18.628 - ( 109.719 - max(0, 91.235 - 172.464+109.719))
=110.579

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Mediwelcome Healthcare Management & Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=26.374/( ( (10.214 + max(-13.104, 0)) + (9.344 + max(27.891, 0)) )/ 2 )
=26.374/( ( 10.214 + 37.235 )/ 2 )
=26.374/23.7245
=111.17 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(28.382 + 0 + 69.297) - (40.902 + 0 + 69.881)
=-13.104

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(32.507 + 0 + 29.232) - (18.628 + 0 + 15.22)
=27.891

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Mediwelcome Healthcare Management & Technology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=9.343/381.517
=2.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mediwelcome Healthcare Management & Technology EBIT Related Terms

Mediwelcome Healthcare Management & Technology EBIT Historical Data

* Premium members only.

The historical data trend for Mediwelcome Healthcare Management & Technology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mediwelcome Healthcare Management & Technology EBIT Chart

Mediwelcome Healthcare Management & Technology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only 8.38 -100.27 -103.99 -47.07 9.30

Mediwelcome Healthcare Management & Technology Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -63.04 -23.68 -23.58 -3.84 13.19

HKSE:02159 vs VEEV, BTSG, TEM: EBIT Comparison

For the Health Information Services subindustry, Mediwelcome Healthcare Management & Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mediwelcome Healthcare Management & Technology EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Mediwelcome Healthcare Management & Technology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mediwelcome Healthcare Management & Technology's EV-to-EBIT falls into.


HKSE:02159
54GF Score
Mediwelcome Healthcare Management & Technology Inc HKSE:02159
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mediwelcome Healthcare Management & Technology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$9.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$9.3 Mil mean?
Mediwelcome Healthcare Management & Technology (HKSE:02159) has a EBIT of HK$9.3 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Mediwelcome Healthcare Management & Technology.
Is Mediwelcome Healthcare Management & Technology's EBIT too high?
Mediwelcome Healthcare Management & Technology's current EBIT is HK$9.3 Mil. Overall, Mediwelcome Healthcare Management & Technology has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mediwelcome Healthcare Management & Technology's EBIT compare to VEEV and BTSG?
Mediwelcome Healthcare Management & Technology's EBIT of HK$9.3 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Mediwelcome Healthcare Management & Technology. Mediwelcome Healthcare Management & Technology's current EBIT is HK$9.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mediwelcome Healthcare Management & Technology stock overvalued right now?
Based on GuruFocus' analysis, Mediwelcome Healthcare Management & Technology (HKSE:02159) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.69, compared to a current price of HK$1.62 — trading 134.8% above its estimated fair value. The current EBIT is HK$9.3 Mil. Mediwelcome Healthcare Management & Technology's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Mediwelcome Healthcare Management & Technology (HKSE:02159), the current EBIT is HK$9.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mediwelcome Healthcare Management & Technology (HKSE:02159) Overvalued in 2026?

Based on GuruFocus' analysis, Mediwelcome Healthcare Management & Technology stock appears to be overvalued. The current stock price of HK$1.62 is trading 134.8% above its estimated GF Value™ of HK$0.69. GuruFocus considers Mediwelcome Healthcare Management & Technology to be Significantly Overvalued.

Key valuation signals for HKSE:02159:

  • EBIT: HK$9.3 Mil
  • GF Value™: HK$0.69 vs. price of HK$1.62 (134.8% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02159 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mediwelcome Healthcare Management & Technology Business Description

Address Wangjingdongyuan Zone 4, Wangjing East Park, 17th Floor, Block B, Greenland Center, Chaoyang District, Beijing, CHN, 100101
Mediwelcome Healthcare Management & Technology Inc is an investment holding company. The Group mainly provides medical conference services, patient education and screening services, and marketing and consulting services, in addition to providing integrated healthcare marketing solutions. Its products and services include Academic Conference Management System, Scientific Research Data Reporting System, the Health/Medical Media Matrix, patient management services, and marketing and consulting services. The Group has only one reportable segment, mainly operating its businesses in the PRC and earning revenue from the PRC.
54GF Score

Get the complete analysis for HKSE:02159

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.62
Price
HK$0.69
GF Value